Bank of New York Mellon
ORIC icon

Bank of New York Mellon’s Oric Pharmaceuticals ORIC Stock Holding History

Bank of New York Mellon’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.38M Buy
220,080
+29,610
+16% +$268K ﹤0.01% 2844
2026
Q1 		$2.41M Buy
190,470
+2,549
+1% +$28.9K ﹤0.01% 2714
2025
Q4 		$1.54M Buy
187,921
+12,207
+7% +$141K ﹤0.01% 2993
2025
Q3 		$2.11M Buy
175,714
+40,680
+30% +$428K ﹤0.01% 2778
2025
Q2 		$1.37M Sell
135,034
-31,120
-19% -$209K ﹤0.01% 2941
2025
Q1 		$927K Sell
166,154
-1,145
-0.7% -$10K ﹤0.01% 3112
2024
Q4 		$1.35M Buy
167,299
+129
+0.1% +$1.18K ﹤0.01% 2961
2024
Q3 		$1.71M Sell
167,170
-19,314
-10% -$191K ﹤0.01% 2830
2024
Q2 		$1.32M Buy
186,484
+71,394
+62% +$639K ﹤0.01% 3035
2024
Q1 		$1.58M Sell
115,090
-3,589
-3% -$42.6K ﹤0.01% 2896
2023
Q4 		$1.09M Buy
118,679
+4,029
+4% +$29.1K ﹤0.01% 3138
2023
Q3 		$694K Buy
114,650
+551
+0.5% +$4.51K ﹤0.01% 3377
2023
Q2 		$885K Buy
114,099
+100,790
+757% +$572K ﹤0.01% 3270
2023
Q1 		$75.9K Hold
13,309
– – ﹤0.01% 4118
2022
Q4 		$78.4K Hold
13,309
– – ﹤0.01% 4165
2022
Q3 		$43K Hold
13,309
– – ﹤0.01% 4346
2022
Q2 		$60K Sell
13,309
-97,131
-88% -$388K ﹤0.01% 4321
2022
Q1 		$590K Sell
110,440
-2,249
-2% -$20.3K ﹤0.01% 3614
2021
Q4 		$1.66M Buy
112,689
+1,875
+2% +$29.2K ﹤0.01% 3110
2021
Q3 		$2.32M Buy
110,814
+28,995
+35% +$588K ﹤0.01% 2900
2021
Q2 		$1.45M Buy
81,819
+5,032
+7% +$110K ﹤0.01% 3202
2021
Q1 		$1.88M Buy
76,787
+3,056
+4% +$96.6K ﹤0.01% 2957
2020
Q4 		$2.5M Buy
73,731
+51,147
+226% +$1.47M ﹤0.01% 2712
2020
Q3 		$564K Sell
22,584
-122
-0.5% -$2.9K ﹤0.01% 3433
2020
Q2 		$766K Buy
+22,706
New +$725K ﹤0.01% 3254

Other funds holding ORIC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Swiss National Bank
Swiss National Bank Zurich, Switzerland $191B AUM 45.21% 1-Year Est. Return
WG
Winton Group London, United Kingdom $3.09B AUM 40.4% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Bank of New York Mellon's ORIC Position: Q2 2026 in Review

Bank of New York Mellon increased its Oric Pharmaceuticals (ORIC) stake by 16% in Q2 2026, buying an estimated $268K and bringing the position to 220,080 shares worth $2.38M. The position accounts for ﹤0.01% of the portfolio, ranked #2844.

Bank of New York Mellon first reported a position in ORIC in Q2 2020 and has held it in 25 quarters since. The position peaked at $2.5M in Q4 2020. 47 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • Bank of New York Mellon held 220,080 shares of Oric Pharmaceuticals worth $2.38M as of Q2 2026.
  • Bank of New York Mellon bought 29,610 Oric Pharmaceuticals shares in Q2 2026, an estimated $268K.
  • Oric Pharmaceuticals made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2844 holding.
  • Bank of New York Mellon first reported a position in Oric Pharmaceuticals in Q2 2020 and has held it in 25 quarters since.
  • Bank of New York Mellon's Oric Pharmaceuticals position peaked at $2.5M in Q4 2020.
  • 47 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.